Pharmafile Logo

Owlstone Medical

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round

Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical trials of Breath Biopsy diagnostic tests and point of care devices for lung cancer, liver disease, and digestive disease 15 January 2025 – Cambridge, UK : Owlstone...

Owlstone Medical Secures $6.5m to Support Development of Breath-based Diagnostics for Infectious Disease

$5m equity investment and initial $1.5m grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the developing world Funding represents the first time the foundation has taken an equity position in a breath diagnostics company Funding will also support enhancement of the Breath Biopsy...

Owlstone Medical Recruits First Patient in Phase 2 Clinical Trial for the Early Detection of Lung Cancer through Breath Biopsy

EVOLUTION phase 2 trial follows successful phase 1 demonstration of proof of concept for a lung cancer screening test and safety of probe Phase 2 study to focus on assessing diagnostic accuracy and optimising test performance 10 October 2023 -- Cambridge, UK -- Owlstone Medical, the global leader in Breath Biopsy for applications in early...

Owlstone Medical Presents Data Demonstrating Progress in Development of Breath Biopsy Test for the Early Detection of Lung Cancer

Cambridge, UK, June 14 2023: Owlstone Medical ('Owlstone'), the global leader in Breath Biopsy for applications in early disease detection and precision medicine, today announced new data on the development of a screening test for the early detection of lung cancer. The results and research progress were presented in two posters at the EACR 2023...

Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection

Cambridge, UK, 17 May 2023: Owlstone Medical ('Owlstone'), the global leader in Breath Biopsy for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ëExhaled Breath Diagnosticsí. The ëEXHALEí project, focused...

Owlstone Medicals ReCIVA Named Invention of the Year in Top 50 Digital Health Awards

Cambridge, UK, December 6, 2016: Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced today that its ReCIVA breath sampling and analysis technology has been named Invention of the Year in the 2017 Top 50 in Digital Health Awards. Each year ahead of the JP Morgan Health Conference in San Francisco, fifty of...

Owlstone Medical and Imperial College Collaborate to Study Underlying Causes of Asthma Exacerbations

Diagnostics company announces its collaboration with Imperial College London

Owlstone Medical Receives CE Mark Approval for Paediatric Disease Breathalyser

Diagnosis company announces that it has developed and received CE mark approval for a paediatric version of the company's disease breathalyser

Owlstone Medical commences next phase in worlds largest breath-based clinical trial for early cancer detection

Diagnostics company announces the expansion of its Lung Cancer Indicator Detection clinical trial, which aims to save 10,000 lives

Owlstone Medical Strengthens Management Team

Diagnostics company announces its three newest staff appointments, following an investment to commercialise its disease breathalyser
https://www.owlstonenanotech.com
breathbiopsy@owlstone.co.uk
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK

+44 (0)1223 428200